For 40 years, Theragenics has developed and manufactured innovative medical devices. Recognized as a global leader in serving the brachytherapy, interventional access, veterinary surgical and wound closure markets, we remain dedicated to improving lives with each and every order we fill. We can’t wait to see what the next 40 years will bring.
Theragenics Corporation was founded in 1981 by scientists from Georgia Tech (Georgia Institute of Technology), with the primary mission to develop radiological devices to treat cancer. Theragenics is a recognized global leader in the manufacture of radioactive brachytherapy seeds for the treatment of localized cancers, primarily prostate cancer. Theragenics substantially diversified its operations beginning in 2005 by expanding into the surgical products business and since 2006 has continued to expand its portfolio of businesses.
An industry pioneer and leader, Theragenics has an unparalleled history of more than 35 years in the manufacture and global supply and distribution of low-dose rate (LDR) brachytherapy seeds for the treatment of prostate cancer, intra-ocular malignancies, and other tumor types with radiosensitivity. We continue to invest and develop innovative brachytherapy solutions to better serve physicians and their patients.
With over 27 years of expertise designing, developing, manufacturing and marketing disposable medical devices, Theragenics Interventional is a leading global provider of vascular and other access products for a diverse range of interventional procedures. Recognized for high quality precision design, our devices are trusted for their robustness and reliability.
For more than 20 years, CP Medical has been a leading U.S. manufacturer of surgical solutions, specializing in products for wound closure as well as for specialty surgical applications. Our deep-rooted experience and innovative solutions for surgical applications have enabled us to expand our product portfolio of suture and wound closure products for the medical market.
Theragenics Interventional introduces the MicroSlide® line of vascular access products for neonatal, pediatric, and smaller vessels. Maintaining the features that are preferred in our current offerings, this gives the clinician an added advantage to size the product to the patient. Patients benefit from being accessed by the appropriately sized products.